What SinoTau does

SinoTau (先通医药) is a Beijing-headquartered radiopharmaceutical company developing, manufacturing, and commercializing diagnostic and therapeutic radiopharmaceuticals across three therapeutic areas: oncology, neurology (with a focus on Alzheimer's disease diagnostics), and cardiovascular disease. Its commercial portfolio comprises two NMPA-approved products: Florbetaben F18 injection (欧韦宁®), China's first approved Aβ-PET imaging agent for Alzheimer's diagnosis (NMPA approval September 2023), and Adenosine Injection (欧达乐®), China's only domestically-produced cardiac loading drug for myocardial perfusion imaging (NMPA approval January 2023). The company maintains a pipeline of approximately ten innovative radiopharmaceutical assets spanning Phase II through NDA stages, including XTR003 (cardiac, Phase IIb), XTR004 (coronary, Phase III), XTR006/MK-6240 (tau PET, FDA NDA accepted), XTR008 (177Lu-Dotatate, NMPA NDA accepted April 2025), and XTR020 (PSMA PET, Phase III).

The company's technological foundation rests on proprietary radiopharmaceutical formulations and vertically integrated capabilities across five production bases (Beijing HQ, Shanghai R&D, Wuxi, Zhongshan, Mianyang), with a sixth Tianjin facility planned. SinoTau leverages strategic partnerships with global radiopharmaceutical leaders including Blue Earth Diagnostics (PSMA imaging), Life Molecular Imaging (Florbetaben/Neuraceq), Lantheus Holdings (MK-6240 tau imaging), and Isotopia Molecular Imaging (Lutetium-177 supply). The company holds 80+ authorized patents and operates a CRO/CDMO subsidiary (Glotope) to monetize excess manufacturing capacity.

SinoTau operates as a B2B pharmaceutical enterprise selling directly to Chinese hospitals through national and provincial tendering processes, with revenue generated from per-unit drug transactions. Its go-to-market relies on academic promotion teams and medical science liaisons engaging nuclear medicine, neurology, and cardiology departments across China's hospital network. With 400-500+ employees, 2024 revenue of 44.1 million yuan against a net loss of 156 million yuan, and over 2.9 billion yuan in cumulative funding, SinoTau filed for a Hong Kong Stock Exchange listing in June 2025 at a post-IPO valuation of 5.19 billion yuan.

Name

SinoTau

Legal name

北京先通国际医药科技股份有限公司

Website

http://www.sinotau.com/

Company type

Private

Founded year

2005

Headcount range

251–500 employees

Short description

SinoTau is a Beijing-based radiopharmaceutical company developing and commercializing diagnostic and therapeutic radiopharmaceuticals for oncology, neurology, and cardiovascular disease, selling directly to Chinese hospitals via provincial tendering and academic promotion teams.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI)

Keywords

• Radiopharmaceuticals
• Nuclear medicine
• PET imaging agents
• Radioligand therapy
• Molecular imaging

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue from sale of radiopharmaceutical drugs including adenosine injection, Florbetaben F 18 injection, and other nuclear medicine products. One-time drug transaction model typical of pharmaceutical commercialization in China.
2. In-license Products Commercialization: Commercialization of imported/in-licensed products including Neuraceq and other partnered radiopharmaceuticals through China's hospital supply network.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

SinoTau (先通医药) develops, manufactures, and commercializes innovative radiopharmaceuticals for precision diagnostics and targeted therapy in oncology, neurology, and cardiovascular disease. The company operates vertically integrated R&D and GMP-certified manufacturing across multiple production bases in China, distributes products through national hospital tendering, and partners with global radiopharmaceutical leaders (Blue Earth Diagnostics, Life Molecular Imaging, Lantheus, Isotopia) for in-licensed products. Two products are commercially launched in China (Florbetaben F18 injection and adenosine injection), with a pipeline of 10+ additional radiopharmaceutical candidates in clinical and regulatory stages.

Differentiator

Problem solved

Functional benefit

Products and services

• 欧韦宁® (Florbetaben F18 Injection) / Neuraceq® 18F-labeled PET radiotracer for detection of beta-amyloid plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of dementia; supplied to hospital nuclear medicine departments.
• 欧达乐® (Adenosine Injection, 20ml:60mg) Adenosine injection used as a pharmacologic stress agent for myocardial perfusion imaging and echocardiographic drug loading tests in cardiac diagnostic procedures; supplied to hospital cardiology departments through SinoTau's hospital distribution network.

Quantifiable outcome

• Post-IPO valuation of 5.19 billion yuan reflects market confidence in pipeline potential and first-mover position in China's radiopharmaceutical sector
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• Blue Earth DiagnosticscoreStrategic or Co-development PartnerStrategic agreement for development and commercialization of PSMA-targeted PET imaging agent for prostate cancer diagnostics in China. SinoTau leverages partnership for access to proprietary PSMA-targeting technology and global development data.
• Life Molecular ImagingcoreStrategic or Co-development PartnerPartnership for regulatory approval and commercialization of Neuraceq (Florbetaben F 18) in China. Neuraceq received regulatory approval for beta-amyloid PET imaging in Alzheimer's disease diagnosis.
• Lantheus HoldingscoreStrategic or Co-development PartnerPartnership for XTR006/MK-6240, a next-generation tau protein PET imaging agent for Alzheimer's disease and neurodegenerative disorders. SinoTau licensed Greater China rights for development and commercialization.
• Isotopia Molecular ImagingcoreTechnology or IntegrationSupply agreement for Lutetium-177 (177Lu), a therapeutic radioisotope used in targeted radionuclide therapy. 177Lu supply enables SinoTau's development of radiopharmaceutical therapeutics.
• Cerveau TechnologiescoreStrategic or Co-development PartnerJoint venture for development and commercialization of molecular imaging agents in China, focusing on innovative radiopharmaceutical products for neurological and oncological applications.

Scale indicators9 records

Recent moves11 records

Expansion highlights5 records

Broad incumbents

• GE HealthCare: Diversified medical imaging and radiopharmaceutical supplier with PET tracer portfolio; broad incumbent serving the same nuclear medicine departments that SinoTau targets.
• Novartis: Pharmaceutical major with leading therapeutic radiopharmaceuticals (Pluvicto, Lutathera); represents the major competitive threat in 177Lu-based targeted radionuclide therapy that SinoTau is building toward.
• Bracco Imaging: Global diagnostic imaging company with a significant radiopharmaceutical portfolio (including through Blue Earth Diagnostics); competes in PET imaging tracers and serves overlapping hospital nuclear medicine customers.

Direct peers

• Lantheus Holdings: U.S. radiopharmaceutical leader (PNT2002, MK-6240 partner) and SinoTau's strategic partner on XTR006; both companies develop and commercialize diagnostic and therapeutic radiopharmaceuticals across oncology and neurology.
• Curium Pharma: World's largest pure-play radiopharmaceutical manufacturer; directly competes with SinoTau in PET/SPECT tracer supply and has scale advantages in global manufacturing and distribution.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with PSMA PET imaging (Illuccix) and pipeline therapeutic assets; directly comparable to SinoTau's PSMA and Lu-177 programs in oncology.
• Life Molecular Imaging: Developer of Florbetaben (Neuraceq) and other neurodegenerative PET tracers; SinoTau's partner on the Florbetaben F18 China program and a comparable player in neurology imaging.
• Blue Earth Diagnostics: Radiopharmaceutical company specializing in PET imaging agents including PSMA-targeted agents; SinoTau's strategic partner and a direct competitor in the prostate cancer imaging space.
• Isotopia Molecular Imaging: Israeli radiopharmaceutical manufacturer supplying Lu-177 and PET tracers; SinoTau's 177Lu supply partner and a comparable company integrating radioisotope production with finished drug supply.

Regional players

• Hengrui Pharmaceuticals: Largest Chinese innovative pharmaceutical company that is actively expanding into radiopharmaceuticals; a domestic competitor pursuing overlapping hospital channels and oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries6 records

Funding overview

Funding rounds5 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SinoTau